CagriSema Dosage Guide
60/100 confidenceComplete guide to CagriSema dosing protocols, administration methods, and safety considerations for research purposes.
NOT Medical Advice
The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.
Detailed Dosage Information
Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides.
Administration Method
Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026.
Research Backing
REDEFINE Phase 3 program. REDEFINE-1 trial: 22.7% weight loss at 68 weeks. REDEFINE-2 (T2D). Novo Nordisk pipeline. FDA submission accepted, response expected 2026.
Side Effects to Monitor
Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions.
Safety Considerations & Risks
Pre-approval combination therapy — full safety profile not yet established. Carries the same black box warning risk as semaglutide (thyroid C-cell tumors in rodents). Pancreatitis risk. No long-term data beyond 68 weeks. Potential for greater lean mass loss given higher total weight loss.